One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/EkudaG7YiY

📢 "3 months after starting that TNFi ... she was still symptomatic" – Lindsay Tom, PA-C Hear Lindsay discuss this PsA case and her data-informed treatment choices with Dr. Saakshi Khattri. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/MOBlwXCFuu https://t.co/3Tv6r7CaQb

Thousands of abstracts. Four days of science. What really matters? Drs. Jack Cush and Arthur Kavanaugh cut through the noise and deliver their take on the biggest stories from #ACR26. Watch LIVE on X, YouTube, Facebook, or https://t.co/ofGKCCNQnE. https://t.co/ms4bWVT3B3

Pre-RA: Antibodies Sort the Risk, Ultrasound Erosions Flag Severity Three ACR 2026 abstracts from the Leeds CCP cohort tested how to triage anti-CCP positive individuals with musculoskeletal symptoms. Serology and a few clinical items carried the prediction, while ultrasound https://t.co/91HG7xPS3o

Efgartigimod: A New Mechanism for Myositis? Abstracts come and go, but new trials and new mechanisms stay with us for the long haul. One of the more interesting new mechanisms is the FcRn drugs, and at ACR Convergence 2026 we got to see positive results from the Phase 3 ALKIVIA https://t.co/cCgItPQSPS

“Age old” biomarkers in ILD and pulmonary fibrosis At #ACR26, there was a poster on senescence being increased in SARD-ILD (systemic autoimmune rheumatic disease – interstitial lung disease) including fibrotic (progressive pulmonary fibrosis), showing epithelial remodeling from https://t.co/cNxgqJIH8T

AI vs Rheumatologist? The Better Answer May Be Both Can artificial intelligence answer patients’ rheumatology questions as well as a rheumatologist? Abstract 2965 at #ACR26 suggests the answer may be yes, but also highlights why physician oversight still matters. https://t.co/RNbCUFjMQo

Why Did the Last Drug Fail? When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ

Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA Which of our RA patients will develop RA-ILD, and how can we better identify these patients? In abstract #2884 at #ACR26 , Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study https://t.co/P96KAcPmWt

It was a beautiful Year in Preview from @AlexisOgdie - here's a summary of her take on what might be to come in rheumatology in the year ahead #ACR26 @RheumNow https://t.co/DneNoUkc7u https://t.co/jlAdwZYAQI

Making the Case for Early Biologics in Lupus A new diagnosis of SLE can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and https://t.co/CmTeHTwzZw

ACR 2026 Day 3 Report https://t.co/7DbbFhEtp4 https://t.co/tCB9tKgTup

Pregnancy After CAR-T in Autoimmune Disease: 14 Pregnancies, No Flares The first multicenter series of pregnancies after CAR T-cell therapy for autoimmune disease reports 8 healthy births and no maternal flares. It is the first dataset of its kind, and the numbers are small. https://t.co/uqWz8GeAmX

Menopause and Rheumatoid Arthritis: Are we asking enough? A study from Mayo Clinic at ACR Convergence, abstract 1849 examines menopause symptom burden in women with and without RA. Using two research datasets, Kristen Young and colleagues conducted a cross-sectional analysis of https://t.co/V3VJXo3z5w

Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA 14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/yC4bhtnTCD